We are live on ! Find out more
BLRX icon

BioLineRX

30 hedge funds and large institutions have $5.09M invested in BioLineRX in 2021 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 9 increasing their positions, 4 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

125% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 4

16% more capital inflows, than outflows

Capital inflows: $776K | Capital outflows: $671K

3% more funds holding

Funds holding: 29 → 30 (+1)

0.13% more ownership

Funds ownership: 5.1% → 5.23% (+0.13%)

20% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 5

47% less call options, than puts

Call options by funds: $54K | Put options by funds: $101K

Holders
30
Holders Change
+1
Holders Change %
+3.45%
% of All Funds
0.46%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
9
Reduced
4
Closed
5
Calls
$54​K
Puts
$101​K
Net Calls
-⁠$47​K
Net Calls Change
+$348​K

BLRX Hedge Fund Activity: Q4 2021 in Review

30 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in BioLineRX (BLRX) for Q4 2021, worth a combined $5.09M — down 24% from $6.69M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of BLRX and 4 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 9 added.

The largest buyer was PVG Asset Management, adding an estimated $218K. The largest seller was Citadel Advisors, exiting entirely with an estimated $430K sold.

  • 30 institutional investors held BioLineRX (BLRX) as of Q4 2021, up from 29 in Q3 2021.
  • Funds reported $5.09M of BioLineRX stock for Q4 2021, down 24% quarter-over-quarter.
  • 4 funds opened new BioLineRX positions in Q4 2021 and 5 closed out, a net change of -1 holder.
  • The largest BioLineRX buyer in Q4 2021 was PVG Asset Management, an estimated $218K added.
  • The largest BioLineRX seller in Q4 2021 was Citadel Advisors, an estimated $430K sold.

Based on aggregated 13F filings for Q4 2021.